Literature DB >> 30245036

Clinical significance of perioperative hyperglycemia in bariatric surgery: evidence for better perioperative glucose management.

Katherine M Meister1, Theadore Hufford1, Chao Tu2, Zhamak Khorgami3, Philip R Schauer1, Stacy A Brethauer1, Ali Aminian4.   

Abstract

BACKGROUND: Uncontrolled hyperglycemia in patients undergoing surgery has been shown to be a risk factor for postoperative complications.
OBJECTIVE: To assess the clinical significance of perioperative hyperglycemia on infectious complications and clinical outcomes in patients undergoing bariatric surgery.
SETTING: Single academic center.
METHODS: Retrospective chart review of all patients who underwent primary laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy between 2013 and 2016 was performed. The association between any elevated perioperative glucose value (hyperglycemia: ≥126 mg/dL) and level of elevation (≥126 or ≥200 mg/dL) with 30-day infectious complications, reoperation, length of hospital stay, and readmission was assessed. Patients who developed early complications (within 3 d of surgery), which could potentially lead to immediate postoperative hyperglycemia, were not included in the analysis. Outcomes of patients with and without diabetes were separately analyzed.
RESULTS: A cohort of 1981 patients was studied, including Roux-en-Y gastric bypass (n = 1171, 59%) and sleeve gastrectomy (n = 810, 41%) patients. In patients with diabetes (n = 751, 38%), perioperative hyperglycemia was independently associated with higher composite infectious complications (defined as presence of any of 6 infectious complications; odds ratio [OR] 3.1, 95% confidence interval [CI] 1.2-8.2, P = .018) and higher readmission rate (OR 2.2, 95% CI 1.1-4.6, P = .027). In patients without diabetes (n = 1230, 62%), 19.2% had perioperative hyperglycemia (≥126 mg/dL). Perioperative hyperglycemia in patients without diabetes was associated with higher composite infectious complications (OR 2.6, 95% CI 1.1-5.5, P = .018) and prolonged length of stay (OR 3.0, 95% CI 1.5-5.9, P = .001).
CONCLUSIONS: An elevated perioperative glucose value is adversely associated with infectious complications and key clinical outcomes after bariatric surgery. The increased risk is correlated with the extent of glucose elevation (dose-response relationship). Our findings highlight the importance of glucose control during the perioperative period in bariatric surgical patients.
Copyright © 2018 American Society for Bariatric Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bariatric surgery; Complication; Diabetes; Glucose; Hyperglycemia; Roux-en-Y gastric bypass; Sleeve gastrectomy; Surgical site infection

Mesh:

Substances:

Year:  2018        PMID: 30245036     DOI: 10.1016/j.soard.2018.07.028

Source DB:  PubMed          Journal:  Surg Obes Relat Dis        ISSN: 1550-7289            Impact factor:   4.734


  4 in total

1.  Association of postoperative glycemic control with outcomes after carotid procedures.

Authors:  Jonathan Bath; Robin L Kruse; Jamie B Smith; Naveen Balasundaram; Todd R Vogel
Journal:  Vascular       Date:  2019-07-25       Impact factor: 1.285

2.  Type 2 Diabetes and HbA1c Predict All-Cause Post-Metabolic and Bariatric Surgery Hospital Readmission.

Authors:  Elisa Morales-Marroquin; Luyu Xie; Luigi Meneghini; Nestor de la Cruz-Muñoz; Jaime P Almandoz; Sunil M Mathew; Benjamin E Schneider; Sarah E Messiah
Journal:  Obesity (Silver Spring)       Date:  2020-11-20       Impact factor: 9.298

3.  The neglected perioperative population of undiagnosed diabetics - a retrospective cohort study.

Authors:  Wei W Teo; Lian K Ti; Lyn L Lean; Edwin Seet; Ambika Paramasivan; Weiling Liu; Jiexun Wang; Vanessa Chua; Lydia Q Liew
Journal:  BMC Surg       Date:  2020-08-18       Impact factor: 2.102

Review 4.  Safety considerations in laparoscopic surgery: A narrative review.

Authors:  Brij Madhok; Kushan Nanayakkara; Kamal Mahawar
Journal:  World J Gastrointest Endosc       Date:  2022-01-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.